Shu-Xia Li, PhD
Staff Affiliate - YNHHCards
Additional Titles
Associate Director, Data Management & Analytics, Center for Outcomes Research & Evaluation (CORE), Yale School of Medicine
Contact Info
About
Copy Link
Titles
Staff Affiliate - YNHH
Positions outside Yale
Associate Director, Data Management & Analytics, Center for Outcomes Research & Evaluation (CORE), Yale School of Medicine
Biography
Dr. Li is an Associate Director of Data Management and Analytics at Yale-New Haven Hospital Centers for Outcomes Research and Evaluation (CORE). She has help initiated and served in a leadership role in CORE’s big data research project. She has had a dynamic research career with 20+ years of diverse and in-depth hands-on experience in building health care quality measures, designing clinical trials and performing data analysis, pre-clinical data analysis, bio-marker discovery, data mining, genomics, proteomics, gene-expression profiling, and bioinformatics application development in both industrial and academic settings. Her current work focuses on bringing new statistical and mathematical tools in health care outcomes research. She has been collaborating with health care outcome researchers and published in phenotyping hospital drug and procedure variation and utilization patterns, health-care cost/value patterns, risk prediction modeling, and imaging analysis using artificial intelligence. She has also actively engaged in hospital quality measures and surveillance tool development in collaboration with Center for Medicare and Medicaid Service (CMS). She is also interested in precision medicine in the era of big data.
Departments & Organizations
Education & Training
- PhD
- Yale University, Biostatistics (2010)
- MS
- Yale Univeristy, Biostatistics (2005)
- PhD
- Ohio University, Molecular and Cellular Biology (1996)
- BS
- Sichuan University, Biology/Genetics (1989)
Research
Copy Link
Overview
Medical Research Interests
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harlan Krumholz, MD, SM
Kumar Dharmarajan, MD, MBA
Zhenqiu Lin, PhD
Andreas Coppi
Haiqun Lin
Arjun Venkatesh, MD, MBA, MHS
Treatment Outcome
Quality of Health Care
Publications
2026
Association of Reproductive Factors with Acute Myocardial Infarction in Young Women: A VIRGO and NHANES case-control study
Dong W, Yang H, Sawano M, Li S, Xu X, Murugiah K, Krumholz H, Lu Y. Association of Reproductive Factors with Acute Myocardial Infarction in Young Women: A VIRGO and NHANES case-control study. American Journal Of Preventive Cardiology 2026, 101700. DOI: 10.1016/j.ajpc.2026.101700.Peer-Reviewed Original ResearchAltmetric
2025
Coronary Artery Disease–Based Polygenic Risk Score in Early-Onset Acute Myocardial Infarction Subtypes
Dong W, Lu Y, Li S, Sawano M, Caraballo C, Liu Y, Khera A, Philippakis A, Dreyer R, Lichtman J, D'Onofrio G, Spatz E, Herrington D, Post W, Rich S, Rotter J, Krumholz H. Coronary Artery Disease–Based Polygenic Risk Score in Early-Onset Acute Myocardial Infarction Subtypes. JACC Advances 2025, 4: 101994. PMID: 40712269, PMCID: PMC12311502, DOI: 10.1016/j.jacadv.2025.101994.Peer-Reviewed Original ResearchCitationsNirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Christian D, Coppi A, Warner F, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Mouslmani M, Hooper W, Putrino D, Carr K, Charnas L, De Jesus M, Nepert D, Abreu P, Ziegler F, Spertus J, Iwasaki A, Krumholz H. Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. The Lancet Infectious Diseases 2025, 25: 936-946. PMID: 40188838, DOI: 10.1016/s1473-3099(25)00073-8.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic
Faust J, Renton B, Bongiovanni T, Chen A, Sheares K, Du C, Essien U, Fuentes-Afflick E, Haywood T, Khera R, King T, Li S, Lin Z, Lu Y, Marshall A, Ndumele C, Opara I, Loarte-Rodriguez T, Sawano M, Taparra K, Taylor H, Watson K, Yancy C, Krumholz H. Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e2438918. PMID: 39392630, PMCID: PMC11581672, DOI: 10.1001/jamanetworkopen.2024.38918.Peer-Reviewed Original ResearchCitationsAltmetricEffect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities
Lu Y, Brush J, Liu Y, Li S, Asher J, Krumholz H. Effect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities. JACC Advances 2024, 3: 101177. PMID: 39220712, PMCID: PMC11364117, DOI: 10.1016/j.jacadv.2024.101177.Peer-Reviewed Original ResearchProcessing and validation of inpatient Medicare Advantage data for use in hospital outcome measures
Kyanko K, Sahay K, Wang Y, Schreiber M, Hager M, Myers R, Johnson W, Zhang J, Yen B, Suter L, Triche E, Li S. Processing and validation of inpatient Medicare Advantage data for use in hospital outcome measures. Health Services Research 2024, 59: e14350. PMID: 38961668, PMCID: PMC11622257, DOI: 10.1111/1475-6773.14350.Peer-Reviewed Original ResearchCitationsAltmetricIncorporating Medicare Advantage Admissions Into the CMS Hospital-Wide Readmission Measure
Kyanko K, Sahay K, Wang Y, Li S, Schreiber M, Hager M, Myers R, Johnson W, Zhang J, Krumholz H, Suter L, Triche E. Incorporating Medicare Advantage Admissions Into the CMS Hospital-Wide Readmission Measure. JAMA Network Open 2024, 7: e2414431. PMID: 38829614, PMCID: PMC11148674, DOI: 10.1001/jamanetworkopen.2024.14431.Peer-Reviewed Original ResearchCitationsAltmetricThe PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024, 138: 884-892.e4. PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchCitationsAltmetricHypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records
Brush J, Lu Y, Liu Y, Asher J, Li S, Sawano M, Young P, Schulz W, Anderson M, Burrows J, Krumholz H. Hypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records. Journal Of The American Heart Association 2024, 13: e033253. PMID: 38686864, PMCID: PMC11179912, DOI: 10.1161/jaha.123.033253.Peer-Reviewed Original ResearchCitationsAltmetricPre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality
Peter D, Li S, Wang Y, Zhang J, Grady J, McDowell K, Norton E, Lin Z, Bernheim S, Venkatesh A, Fleisher L, Schreiber M, Suter L, Triche E. Pre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality. BMJ Open 2024, 14: e077394. PMID: 38553067, PMCID: PMC10982775, DOI: 10.1136/bmjopen-2023-077394.Peer-Reviewed Original ResearchCitationsAltmetric
News
Copy Link
News
- July 02, 2024
Yale Faculty Members Named to JACC Editorial Board
- May 28, 2024
Next Generation Research Uses Real-World Data to Identify Most Effective Hypertension Drugs for Patients
- December 18, 2022
Yale Insights in Cardiovascular Medicine: 2022
- May 03, 2022
Surprising Risk Factors May Predict Heart Attacks in Young Women
Get In Touch
Copy Link